{"id":565039,"date":"2021-09-22T10:40:01","date_gmt":"2021-09-22T10:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=565039"},"modified":"2021-09-22T10:40:01","modified_gmt":"2021-09-22T10:40:01","slug":"ulcerative-colitis-epidemiology-forecast-report-2030-ulcerative-colitis-epidemiology-analysis-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ulcerative-colitis-epidemiology-forecast-report-2030-ulcerative-colitis-epidemiology-analysis-2030-delveinsight_565039.html","title":{"rendered":"Ulcerative Colitis Epidemiology Forecast Report 2030 | Ulcerative Colitis Epidemiology Analysis 2030 | DelveInsight"},"content":{"rendered":"
\n
\"Ulcerative<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Ulcerative Colitis (UC) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Ulcerative Colitis (UC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n

DelveInsight launched a new report on Ulcerative Colitis Epidemiology Forecast, 2030.<\/a><\/strong><\/p>\n

Ulcerative colitis is usually only in the innermost lining of the large intestine (colon) and rectum. Forms range from mild to severe. Having ulcerative colitis puts a patient at increased risk of developing colon cancer.<\/p>\n

DelveInsight’s ‘Ulcerative Colitis Epidemiology Forecast to 2030‘ <\/a><\/strong>report delivers an in-depth understanding of the disease, historical and forecasted Ulcerative Colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key highlights from the Ulcerative Colitis Epidemiology Report:<\/strong><\/p>\n

    \n
  1. \n

    The total prevalent population of Ulcerative Colitis<\/a><\/strong> in the 7MM in 2020 was 2,201,831. These cases are expected to rise by 2030, during the forecast period [2021–2030]. <\/p>\n<\/li>\n

  2. \n

    According to DelveInsight’s analysis, in the 7MM, the United States reported the highest prevalent cases of Ulcerative Colitis, i.e., 1,008,823 which accounted for nearly 46% of the total 7MM cases, in the year 2020. <\/p>\n<\/li>\n

  3. \n

    Among the EU-5 countries, the highest number of cases of Ulcerative Colitis was in Germany, i.e., 342,785 cases in the year 2020. <\/p>\n<\/li>\n<\/ol>\n

    Visit for more @ Ulcerative Colitis Epidemiology Insights<\/a><\/strong><\/p>\n

    Scope of the Ulcerative Colitis Epidemiology report:<\/strong><\/p>\n

      \n
    1. \n

      The Ulcerative Colitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.<\/p>\n<\/li>\n

    2. \n

      The Ulcerative Colitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Ulcerative Colitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).<\/p>\n<\/li>\n

    3. \n

      The report provides insight into the historical and forecasted patient pool of Ulcerative Colitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.<\/p>\n<\/li>\n

    4. \n

      The report helps to recognize the growth opportunities in the 7MM concerning the patient population.<\/p>\n<\/li>\n

    5. \n

      The report assesses the disease risk and burden and highlights the unmet needs of Ulcerative Colitis.<\/p>\n<\/li>\n

    6. \n

      The report provides the segmentation of the Ulcerative Colitis epidemiology.<\/p>\n<\/li>\n<\/ol>\n

      Table of Contents:<\/strong><\/p>\n

      1. Key Insights<\/p>\n

      2. Executive Summary of Ulcerative Colitis<\/p>\n

      3. Ulcerative Colitis Epidemiology Overview at a Glance<\/p>\n

      4. Ulcerative Colitis: Disease Background and Overview<\/p>\n

      5. Epidemiology and Patient Population<\/p>\n

      6. Case Reports<\/p>\n

      7. Country Wise-Epidemiology of Ulcerative Colitis <\/p>\n

      8. Appendix<\/p>\n

      9. DelveInsight Capabilities<\/p>\n

      10. Disclaimer<\/p>\n

      11. About DelveInsight<\/p>\n

      Read more on Ulcerative Colitis Epidemiological Insights<\/a><\/strong><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight’s ‘Ulcerative Colitis (UC) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Ulcerative Colitis (UC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-565039","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/565039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=565039"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/565039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=565039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=565039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=565039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}